TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with two marketed products, ChondroCelect and ChondroMimetic, and a strong pipeline with clinical stage adipose stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium), and Madrid (Spain), and has facilities in Cambridge (UK) and Sittard- Geleen (the Netherlands). For more information please visit www.tigenix.com.
See all stories on Tigenix @ Daily Dose Equities.
